Regentis Biomaterials Ltd. Sample Contracts
UNDERWRITING AGREEMENT between REGENTIS BIOMATERIALS LTD. and THINKEQUITY LLC as Representative of the Several Underwriters REGENTIS BIOMATERIALS LTD.Underwriting Agreement • May 5th, 2025 • Regentis Biomaterials Ltd. • Pharmaceutical preparations • New York
The undersigned, Regentis Biomaterials Ltd., a corporation formed under the laws of the State of Israel (collectively with its affiliates, including, without limitation, all entities disclosed or described in the Registration Statement (as hereinafter defined) as being affiliates of Regentis Biomaterials Ltd. (the “Company”), hereby confirms its agreement (this “Agreement”) with ThinkEquity LLC (hereinafter referred to as “you” (including its correlatives) or the “Representative”) and with the other underwriters named on Schedule 1 hereto for which the Representative is acting as representative (the Representative and such other underwriters being collectively called the “Underwriters” or, individually, an “Underwriter”) as follows:
indemnification agreementIndemnification Agreement • May 5th, 2025 • Regentis Biomaterials Ltd. • Pharmaceutical preparations
THIS INDEMNIFICATION AGREEMENT (the “Agreement”), dated as of [_______] [__], 2025, is entered into by and between Regentis Biomaterials Ltd., an Israeli company (the “Company”), and the undersigned Director or Officer of the Company whose name appears on the signature page hereto officer (the “Indemnitee”).
INDEMNIFICATION AGREEMENTIndemnification Agreement • December 7th, 2022 • Regentis Biomaterials Ltd. • Pharmaceutical preparations
THIS INDEMNIFICATION AGREEMENT (the “Agreement”), dated as of [_____], 2022 , is entered into by and between Regentis Biomaterials Ltd., an Israeli company whose address is 12 Ha’ilan Street, Northern Industrial Zone, P.O. Box 260 Or-Akiva 306000, Israel (the “Company”), and the undersigned Director or Officer of the Company whose name appears on the signature page attached hereto (the “Indemnitee”).
AGREEMENTService Agreement • December 7th, 2022 • Regentis Biomaterials Ltd. • Pharmaceutical preparations
This Agreement is entered into as of on December 5, 2022, effective as of March 31, 2022 (the “Commencement Date”), by and between Regentis Biomaterials Ltd., a company incorporated in the State of Israel whose address is 60 Medinat Hayehudim Street, Entrance C. Herzeliya, Israel (the “Company”), and Mr. Noam Band, ID no. [_________], of [______________]., Tel Aviv, Israel (the “Service Provider”).
Form of Representative’s Warrant AgreementPurchase Warrant Agreement • May 5th, 2025 • Regentis Biomaterials Ltd. • Pharmaceutical preparations
THIS WARRANT TO PURCHASE ORDINARY SHARES (the “Warrant”) certifies that, for value received, THINKEQUITY LLC or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after ____, 20253, (the “Initial Exercise Date”) and, in accordance with FINRA Rule 5110(g)(8)(A), prior to at 5:00 p.m. (Eastern Time) on [__, 2030]4(the “Termination Date”) but not thereafter, to subscribe for and purchase from Regentis Biomaterials Ltd., an Israeli corporation (the “Company”), up to ______ (the “Warrant Shares”) ordinary shares, par value NIS 0.01 per share, of the Company (the “Ordinary Shares”), as subject to adjustment hereunder. The purchase price of one Ordinary Share under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b). This Warrant is being issued pursuant to that certain underwriting agreement, dated as of [___], 2025, between the Company and ThinkEquity LLC, as
FORM OF PRE-FUNDED WARRANT TO PURCHASE ORDINARY SHARES REGENTIS BIOMATERIALS, LTD.Security Agreement • June 18th, 2026 • Regentis Biomaterials Ltd. • Orthopedic, prosthetic & surgical appliances & supplies • New York
THIS PRE-FUNDED WARRANT TO PURCHASE ORDINARY SHARES (this “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Issue Date and until this Warrant is exercised in full (the “Termination Date”) but not thereafter, to subscribe for and purchase from Regentis Biomaterials, Ltd., a corporation formed under the laws of the State of Israel (the “Company”), up to _________ Ordinary Shares (as subject to adjustment hereunder, the “Warrant Shares”). The purchase price of one Warrant Share under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • June 18th, 2026 • Regentis Biomaterials Ltd. • Orthopedic, prosthetic & surgical appliances & supplies • New York
This SECURITIES PURCHASE AGREEMENT (this “Agreement”) is dated as of June 17, 2026, between Regentis Biomaterials Ltd., a company incorporated under the laws of the State of Israel, having its registered office at Puglisi & Associates, 850 Library Ave., Suite 204, Newark DE 19711 (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
UNDERWRITING AGREEMENT between REGENTIS BIOMATERIALS LTD. and THINKEQUITY LLC as Representative of the Several Underwriters REGENTIS BIOMATERIALS LTD.Underwriting Agreement • July 7th, 2025 • Regentis Biomaterials Ltd. • Pharmaceutical preparations • New York
The undersigned, Regentis Biomaterials Ltd., a corporation formed under the laws of the State of Israel (collectively with its affiliates, including, without limitation, all entities disclosed or described in the Registration Statement (as hereinafter defined) as being affiliates of Regentis Biomaterials Ltd. (the “Company”), hereby confirms its agreement (this “Agreement”) with ThinkEquity LLC (hereinafter referred to as “you” (including its correlatives) or the “Representative”) and with the other underwriters named on Schedule 1 hereto for which the Representative is acting as representative (the Representative and such other underwriters being collectively called the “Underwriters” or, individually, an “Underwriter”) as follows:
UNDERWRITING AGREEMENT between REGENTIS BIOMATERIALS LTD. and THINKEQUITY LLC as Representative of the Several Underwriters REGENTIS BIOMATERIALS LTD.Underwriting Agreement • December 5th, 2025 • Regentis Biomaterials Ltd. • Pharmaceutical preparations • New York
The undersigned, Regentis Biomaterials Ltd., a corporation formed under the laws of the State of Israel (collectively with its affiliates, including, without limitation, all entities disclosed or described in the Registration Statement (as hereinafter defined) as being affiliates of Regentis Biomaterials Ltd. (the “Company”), hereby confirms its agreement (this “Agreement”) with ThinkEquity LLC (hereinafter referred to as “you” (including its correlatives) or the “Representative”) and with the other underwriters named on Schedule 1 hereto for which the Representative is acting as representative (the Representative and such other underwriters being collectively called the “Underwriters” or, individually, an “Underwriter”) as follows:
AMENDED AND RESTATED SUPPLY AGREEMENTSupply Agreement • November 4th, 2022 • Regentis Biomaterials Ltd. • Pharmaceutical preparations • Delaware
This Amended and Restated Supply Agreement (this “Agreement”) is entered into, effective as of January 6, 2009 (the “Effective Date”) by and between
SERIES B PREFERRED SHARE PURCHASE AGREEMENTSeries B Preferred Share Purchase Agreement • December 7th, 2022 • Regentis Biomaterials Ltd. • Pharmaceutical preparations
THIS SERIES B PREFERRED SHARE PURCHASE AGREEMENT (the “Agreement”) is entered into on and as of this 2nd day of August, 2007, by and among (i) Regentis Biomaterials Ltd., a company organized under the laws of the State of Israel, Israeli Company No. 513585240, located at Matam-Advanced Technology Center, Building No. 30, POB 15054, Haifa 31905, Israel (the “Company”); (ii) The Technological Incubator Founded by the Technion R&D Foundation Ltd., a company organized under the laws of the State of Israel, Israeli Company No. 510340677, located at Matam-Advanced Technology Center, Building No. 30, POB 15054, Haifa 31905, Israel (the “Incubator”); (iii) Dr. Dror Seliktar of Bio-Medical Engineering Department, Technion, Technion City, Haifa 32000, Israel (“Seliktar”); (iv) Mr. Yehiel Tal of 6 Hamaish Street, Zichron Yaakov, Israel (“Tal”) (Seliktar and Tal each a “Founder” and collectively the “Founders”); and (iv) the investors listed on Schedule A to this Agreement (each, an “Investor” and
SERVICES AGREEMENTServices Agreement • November 4th, 2022 • Regentis Biomaterials Ltd. • Pharmaceutical preparations • Delaware
UNDERWRITING AGREEMENT between REGENTIS BIOMATERIALS LTD. and THINKEQUITY LLC as Representative of the Several Underwriters REGENTIS BIOMATERIALS LTD.Underwriting Agreement • September 30th, 2025 • Regentis Biomaterials Ltd. • Pharmaceutical preparations • New York
The undersigned, Regentis Biomaterials Ltd., a corporation formed under the laws of the State of Israel (collectively with its affiliates, including, without limitation, all entities disclosed or described in the Registration Statement (as hereinafter defined) as being affiliates of Regentis Biomaterials Ltd. (the “Company”), hereby confirms its agreement (this “Agreement”) with ThinkEquity LLC (hereinafter referred to as “you” (including its correlatives) or the “Representative”) and with the other underwriters named on Schedule 1 hereto for which the Representative is acting as representative (the Representative and such other underwriters being collectively called the “Underwriters” or, individually, an “Underwriter”) as follows:
AMENDED AND RESTATED INVESTOR RIGHTS AGREEMENTInvestor Rights Agreement • May 5th, 2025 • Regentis Biomaterials Ltd. • Pharmaceutical preparations
THIS AMENDED AND RESTATED INVESTORS’ RIGHTS AGREEMENT (this “Agreement”) made as of the 5th day of February 2016, by and among Regentis Biomaterials Ltd., a company organized under the laws of the State of Israel, Israeli Company No. 513585240, located at 12 Ha’ilan street, Northern Industrial Zone, P.O.B 260, Or Akiva 30600, Israel(the “Company”), the individuals and entities identified in Schedule 1 attached hereto (collectively, the “Series A Preferred Holders”), the individuals and entities identified in Schedule 2 attached hereto ( the “Series B Preferred Holders”); the individuals and entities identified in Schedule 3 attached hereto (collectively, the “Series C Preferred Holders”), the individuals and entities identified in Schedule 4 attached hereto ( the “Series D Preferred Holders” and together with the Series A Preferred Holders and the Series B Preferred, Series C Preferred the “Preferred Holders”); The Company, the Series A Preferred Holders Series B Preferred Holders the
Form of Placement Agent WarrantPlacement Agent Agreement • June 18th, 2026 • Regentis Biomaterials Ltd. • Orthopedic, prosthetic & surgical appliances & supplies
THIS WARRANT TO PURCHASE ORDINARY SHARES (the “Warrant”) certifies that, for value received, ______ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after December 14, 2026, (the “Initial Exercise Date”) and, in accordance with FINRA Rule 5110(g)(8)(A), prior to at 5:00 p.m. (Eastern Time) on June 14, 2031 (the “Termination Date”) but not thereafter, to subscribe for and purchase from Regentis Biomaterials Ltd., an Israeli corporation (the “Company”), up to ______ (the “Warrant Shares”) ordinary shares, no par value per share, of the Company (the “Ordinary Shares”), as subject to adjustment hereunder. The purchase price of one Ordinary Share under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b). This Warrant is being issued pursuant to that certain Placement Agency Agreement, dated as of June 17, 2026, between the Company and ThinkEquity LLC, as
AMENDMENT # 2 TO BRIDGE LOAN AGREEMENTBridge Loan Agreement • July 7th, 2025 • Regentis Biomaterials Ltd. • Pharmaceutical preparations
This Amendment (the “Amendment”) is made with effect as of March 31, 2025 (the “Effective Date”) by and among Regentis Biomaterials Ltd., a company, incorporated under the laws of Israel, (the “Company”) and the lenders identified in Schedule A attached hereto (the “Lenders”). The Company and the Lenders shall each be referred to as a “Party” and collectively as the “Parties”.
AMENDMENT # 1 TO BRIDGE LOAN AGREEMENTBridge Loan Agreement • May 5th, 2025 • Regentis Biomaterials Ltd. • Pharmaceutical preparations
This Amendment (the “Amendment”) is made with effect as of November 12, 2024 (the “Effective Date”) by and among Regentis Biomaterials Ltd., a company, incorporated under the laws of Israel, (the "Company") and the lenders identified in Schedule A attached hereto (the "Lenders"). The Company and the Lenders shall each be referred to as a "Party" and collectively as the "Parties".
FORM OF REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • June 18th, 2026 • Regentis Biomaterials Ltd. • Orthopedic, prosthetic & surgical appliances & supplies
This Registration Rights Agreement (this “Agreement”) is made and entered into as of June 17, 2026, between Regentis Biomaterials Ltd., a company incorporated under the laws of the State of Israel (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”).
Form of Representative’s Warrant AgreementPurchase Warrant Agreement • May 1st, 2026 • Regentis Biomaterials Ltd. • Orthopedic, prosthetic & surgical appliances & supplies
THIS WARRANT TO PURCHASE ORDINARY SHARES (the “Warrant”) certifies that, for value received, ___________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after _____, 20263, (the “Initial Exercise Date”) and, in accordance with FINRA Rule 5110(g)(8)(A), prior to at 5:00 p.m. (Eastern Time) on ______, 20314 (the “Termination Date”) but not thereafter, to subscribe for and purchase from Regentis Biomaterials Ltd., an Israeli corporation (the “Company”), up to ______5 (the “Warrant Shares”) ordinary shares, no par value per share, of the Company (the “Ordinary Shares”), as subject to adjustment hereunder. The purchase price of one Ordinary Share under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b). This Warrant is being issued pursuant to that certain underwriting agreement, dated as of ________, 2026 , between the Company and ThinkEquity LLC, as r
ADDENDUM # 1 TO LOAN AGREEMENTLoan Agreement • May 5th, 2025 • Regentis Biomaterials Ltd. • Pharmaceutical preparations
This Amendment and Addendum (the “Addendum”) is made with effect as of November 19, 2024 (the “Effective Date”) by and among Regentis Biomaterials Ltd., a company, incorporated under the laws of Israel (the “Company”) and the lenders identified in Schedule A attached hereto (each, a “Lender” and collectively, the “Lenders”). The Company and the Lenders shall each be referred to as a “Party” and collectively as the “Parties”.
AMENDED AND RESTATED AMENDMENT #1 TO LOAN AGREEMENTLoan Agreement • July 7th, 2025 • Regentis Biomaterials Ltd. • Pharmaceutical preparations
This Amendment (also the “Amendment”) is made with effect as of July 1, 2025 (the “Effective Date”) by and among Regentis Biomaterials Ltd., a company, incorporated under the laws of Israel, (the “Company”) and the lenders identified in Schedule A attached hereto (the “Lenders”). The Company and the Lenders shall each be referred to as a “Party” and collectively as the “Parties”.
UNDERWRITING AGREEMENT between REGENTIS BIOMATERIALS LTD. and THINKEQUITY LLC as Representative of the Several Underwriters REGENTIS BIOMATERIALS LTD.Underwriting Agreement • May 1st, 2026 • Regentis Biomaterials Ltd. • Orthopedic, prosthetic & surgical appliances & supplies • New York
The undersigned, Regentis Biomaterials Ltd., a corporation formed under the laws of the State of Israel (collectively with its affiliates, including, without limitation, all entities disclosed or described in the Registration Statement (as hereinafter defined) as being affiliates of Regentis Biomaterials Ltd. (the “Company”), hereby confirms its agreement (this “Agreement”) with ThinkEquity LLC (hereinafter referred to as “you” (including its correlatives) or the “Representative”) and with the other underwriters named on Schedule 1 hereto for which the Representative is acting as representative (the Representative and such other underwriters being collectively called the “Underwriters” or, individually, an “Underwriter”) as follows:
AMENDED AND RESTATED AMENDMENT #3 TO BRIDGE LOAN AGREEMENTBridge Loan Agreement • July 7th, 2025 • Regentis Biomaterials Ltd. • Pharmaceutical preparations
This Amendment (the “Amendment”) is made with effect as of July 1, 2025 (the “Effective Date”) by and among Regentis Biomaterials Ltd., a company, incorporated under the laws of Israel, (the “Company”) and the lenders identified in Schedule A attached hereto (the “Lenders”). The Company and the Lenders shall each be referred to as a “Party” and collectively as the “Parties”.
FORM OF WARRANT TO PURCHASE ORDINARY SHARES REGENTIS BIOMATERIALS, LTD.Warrant Agreement • June 18th, 2026 • Regentis Biomaterials Ltd. • Orthopedic, prosthetic & surgical appliances & supplies • New York
THIS WARRANT TO PURCHASE ORDINARY SHARES (this “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Issue Date and on or prior to 5:00 p.m. (New York City time) on [____]1, 2031 (the “Termination Date”) but not thereafter, to subscribe for and purchase from Regentis Biomaterials, Ltd., a corporation formed under the laws of the State of Israel (the “Company”), up to _________ Ordinary Shares (as subject to adjustment hereunder, the “Warrant Shares”). The purchase price of one Warrant Share under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
ADDENDUM # 1 TO CONVERTIBLE LOAN AGREEMENTConvertible Loan Agreement • May 5th, 2025 • Regentis Biomaterials Ltd. • Pharmaceutical preparations
This Amendment and Addendum (the “Addendum”) is made with effect as of October 15, 2024 (the “Effective Date”) by and among Regentis Biomaterials Ltd., a company, incorporated under the laws of Israel (the “Company”) and the lenders identified in Schedule A attached hereto (each, a “Lender” and collectively, the “Lenders”). The Company and the Lenders shall each be referred to as a “Party” and collectively as the “Parties”.
BRIDGE LOAN AGREEMENTBridge Loan Agreement • July 7th, 2025 • Regentis Biomaterials Ltd. • Pharmaceutical preparations • Tel-Aviv
This Bridge Loan Agreement (“Agreement”) is made as of the 09 day of April 2025 (“Effective Date”) by and among Regentis Biomaterials Ltd., a company, incorporated under the laws of Israel (the “Company”) and the lenders identified in Schedule A attached hereto (each, a “Lender” and collectively, the “Lenders”). The Company and the Lenders shall each be referred to as a “Party” and collectively as the “Parties”.
SETTLEMENT AGREEMENTSettlement Agreement • May 5th, 2025 • Regentis Biomaterials Ltd. • Pharmaceutical preparations • Tel-Aviv
This Settlement Agreement (“Agreement”) is entered and made effective as of the 1rst day of December 2024 (“Effective Date”) by and among Regentis Biomaterials Ltd., a company, incorporated under the laws of Israel (the “Company”) and Professor Eli Hazum, I.D. 042872317 (the “Lender” or the “CEO”). The Company and the CEO shall each be referred to as a “Party” and collectively as the “Parties”.
CONVERTIBLE LOAN AGREEMENTConvertible Loan Agreement • May 5th, 2025 • Regentis Biomaterials Ltd. • Pharmaceutical preparations
THIS CONVERTIBLE LOAN AGREEMENT (the “Agreement”) is made as of March 29, 2020 (the “Effective Date”), by and among Regentis Biomaterials Ltd., a company, incorporated under the laws of Israel (the “Company”) and the lenders identified in Schedule 1 attached hereto (each, a “Lender” and collectively, the “Lenders”). The Company and the Lenders shall each be referred to as a “Party” and collectively as the “Parties”.
AMENDED AND RESTATED AMEDNEMENT #1 TO BRIDGE LOAN AGREEMENTBridge Loan Agreement • July 7th, 2025 • Regentis Biomaterials Ltd. • Pharmaceutical preparations
This Amendment (also the “Amendment”) is made with effect as of July 01, 2025 (the “Effective Date”) by and among Regentis Biomaterials Ltd., a company, incorporated under the laws of Israel, (the “Company”) and the lenders identified in Schedule A attached hereto (the “Lenders”). The Company and the Lenders shall each be referred to as a “Party” and collectively as the “Parties”.
FORM OF PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • June 18th, 2026 • Regentis Biomaterials Ltd. • Orthopedic, prosthetic & surgical appliances & supplies • New York
AMENDED AND RESTATED AMENDMENT #2 TO SETTLEMENT AGREEMENTSettlement Agreement • July 7th, 2025 • Regentis Biomaterials Ltd. • Pharmaceutical preparations
This Amendment (also the “Amendment”) is made with effect as of July 1, 2025 (the “Effective Date”) by and among Regentis Biomaterials Ltd., a company, incorporated under the laws of Israel, (the "Company") and Professor Eli Hazum I.D. 042872317 (the "Lender"). The Company and the Lenders shall each be referred to as a "Party" and collectively as the "Parties".
BRIDGE LOAN AGREEMENTBridge Loan Agreement • May 5th, 2025 • Regentis Biomaterials Ltd. • Pharmaceutical preparations • Tel-Aviv
This Bridge Loan Agreement (“Agreement”) is made as of the October 15, 2024 (“Effective Date”) by and among Regentis Biomaterials Ltd., a company, incorporated under the laws of Israel (the “Company”) and the lenders identified in Schedule A attached hereto (each, a “Lender” and collectively, the “Lenders”). The Company and the Lenders shall each be referred to as a “Party” and collectively as the “Parties”.